8.08
0.00 (0.0%)
0.00 (0.0%)
Upgrade to Real-Time
Premarket
| Volume | 53 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| BELLUS Health Inc | BLU | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.00 | 0.0% | 8.08 | 08:06:46 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 8.08 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 2 | 53 | - | 5.45 - 12.69 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 07:02:07 | 1 | $ 7.71 | USD |
Period:
Draw Mode:
BELLUS Health Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 1.02B | 125.79M | 125.79M | $ 15.11k | $ - | - | -11.90 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | - | - | - |
BELLUS Health News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical BLU Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 7.51 | 8.1572 | 7.45 | 7.99 | 398,951 | 0.57 | 7.59% |
| 1 Month | 8.29 | 8.78 | 7.30 | 7.89 | 627,218 | -0.21 | -2.53% |
| 3 Months | 8.95 | 10.35 | 7.30 | 8.72 | 583,786 | -0.87 | -9.72% |
| 6 Months | 9.36 | 12.69 | 7.30 | 9.85 | 616,648 | -1.28 | -13.68% |
| 1 Year | 5.93 | 12.69 | 5.45 | 8.67 | 815,038 | 2.15 | 36.26% |
| 3 Years | 8.91 | 12.69 | 2.01 | 5.60 | 1,429,631 | -0.83 | -9.32% |
| 5 Years | 7.12 | 12.69 | 2.01 | 5.62 | 1,283,185 | 0.96 | 13.48% |
BELLUS Health Description
| BELLUS Health Inc is a clinical-stage biopharmaceutical development company advancing novel therapeutics for conditions with a high unmet medical need, including BLU-5937, P2X3 antagonist that has the potential to be a best-in-class therapeutic for chronic cough. The company operates in one business segment namely, the development of drug candidates for health solutions. |